2015

1. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

   Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403